PREVENTION AND TREATMENT OF INFLAMMATION-INDUCED AND/OR IMMUNE-MEDIATED BONE LOSS

• US 20110275584A1
• Filed: 05/11/2011
• Published: 11/10/2011
• Est. Priority Date: 09/22/2003
• Status: Abandoned Application

• Current Assignee: onepharm Research & Development GmbH
• Original Assignee: onepharm Research & Development GmbH
• Inventors: VOLKMANN, Ariane, WILCKENS, Thomas
• Application Number:
  US13/105,434
• Publication Number:
  US 20110275584A1
• Time in Patent Office: Days
• US Class Current: 514/33
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 31/215 of carboxylic acids
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to the use of an 11-β-HSD-type 1 and/or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.

Claims

1. A method of prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage in a patient in need thereof, comprising the step of administering to said patient a pharmaceutical composition comprising, as an active ingredient, an 11-β

-HSD-type 1 and/or type 2 inhibitor or a salt thereof.

2. The method of claim 1, wherein said patient is a mammal.

3. The method of claim 2, wherein the mammal is a human.

4. The method of claim 1, wherein said inflammation-induced and/or immune-mediated loss of bone and/or cartilage is caused by at least one disease selected from periodontitis, osteoporosis, postmenopausal osteoporosis, arthritis, infectious diseases, bone loss by HIV, tooth loss, bone marrow inflammation, synovial inflammation, cartilage and/or bone erosion, or proteoglycan damage, and wherein said at least one disease is treated by said administration.

5. The method of claim 4, wherein said arthritis is juvenile chronic arthritis, adjuvant arthritis, osteoarthritis, and/or rheumatoid arthritis.

6. The method of claim 1, wherein the pharmaceutical composition comprises at least one 11-β

-HSD-type 1 and/or type 2 inhibitor in combination with at least one active ingredient being effective in the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.

7. The method of claim 1, wherein the pharmaceutical composition is administered in a dose of 5 to 100 mg/kg body weight per day.

8. The method of claim 1, wherein the pharmaceutical composition is administered orally, sublingually, intravenously, intramuscularly, intraarticularly, intraarterially, intramedullarily, intrathecally, intraventricularly, intraocularly,intracerebrally, intracranially, respiratorally, intratracheally, nasopharyngeally, transdermally, intradermally, subcutaneously, intraperitoneally, intranasally, enterally, topically, via rectal means, via infusion and/or via implant.

9. The method of claim 8, wherein the pharmaceutical composition is administered orally.

10. A pharmaceutical composition comprising, as an active ingredient, an 11-β

-HSD-type 1 and/or type 2 inhibitor or a salt thereof.

11. The pharmaceutical composition of claim 10, wherein the 11-β

-HSD-type 1 and/or type 2 inhibitor is 18-β

-glycyrrhetinic acid.

12. The pharmaceutical composition of claim 10, wherein the 11-β

-HSD-type 1 and/or type 2 inhibitor is selected from the group consisting of the following formulas;

13. The pharmaceutical composition of claim 10, wherein the 11-β

-HSD-type 1 and/or type 2 inhibitor has the structure of formula I;

14. The pharmaceutical composition of claim 10, wherein the 11-β

-HSD-type 1 and/or type 2 inhibitor is selected from the group consisting of the following formulas;

15. The pharmaceutical composition of claim 10, wherein the 11-β

-HSD-type 1 and/or type 2 inhibitor has the structure of formula II;

16. The pharmaceutical composition of claim 10, wherein the 11-β

-HSD-type 1 and/or type 2 inhibitor is;

17. The pharmaceutical composition of claim 10, wherein the 11-β

-HSD-type 1 and/or type 2 inhibitor is;

18. The pharmaceutical composition of claim 12, wherein the derivative of glycyrrhetinic acid is selected from glycyrrhizin, glycyrrhizinic acid or carbenoxolone.

19. The pharmaceutical composition of claim 10, wherein the 11-β

-HSD-type 1 and/or type 2 inhibitor is 11-α

-OH-progesterone or 11-β

-OH progesterone.